DaVita (DVA) Expected to Announce Earnings on Tuesday

Posted by Francis Steltz on Jul 28th, 2026

DaVita (NYSE:DVA – Get Free Report) is projected to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of $3.88 per share and revenue of $3.4963 billion for the quarter. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the previous year, the business earned $2.00 EPS. The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. On average, analysts expect DaVita to post $15 EPS for the current fiscal year and $18 EPS for the next fiscal year.

DaVita Stock Performance

Shares of NYSE:DVA traded up $2.78 on Tuesday, hitting $239.09. The company’s stock had a trading volume of 81,229 shares, compared to its average volume of 932,146. The stock’s 50-day moving average is $214.34 and its two-hundred day moving average is $169.95. The company has a market capitalization of $15.35 billion, a price-to-earnings ratio of 22.18, a price-to-earnings-growth ratio of 0.77 and a beta of 0.88. DaVita has a 12 month low of $101.00 and a 12 month high of $240.22.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DaVita

A number of institutional investors have recently bought and sold shares of DVA. Caitlin John LLC acquired a new stake in DaVita during the 4th quarter worth about $34,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita in the second quarter worth about $43,000. Kestra Advisory Services LLC purchased a new position in shares of DaVita in the fourth quarter worth approximately $45,000. iSAM Funds UK Ltd purchased a new position in shares of DaVita in the third quarter worth approximately $46,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of DaVita during the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

DVA has been the topic of a number of research analyst reports. Barclays raised their price objective on shares of DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 8th. TD Cowen increased their price target on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th. Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and lifted their price target for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Truist Financial lifted their target price on DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $216.50.

Get Our Latest Stock Analysis on DaVita

About DaVita

(Get Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.